Concern about high prices for new breakthrough medicines is prompting a push for greater transparency on pricing and reimbursement, with growing demand for the sharing of information on actual market (net) prices in a way that threatens the confidentiality of the pricing deals companies negotiate with payers in individual markets. Pharma firms are fiercely protective of their ‘list’ prices and the confidentiality of the negotiated deals that reduce these prices to the prices